Method validation
Method validation
Based on CLIA regulation before implementation every method in a clinical laboratory should be validated. Validation process assures that performance characteristics of a laboratory test are good enough to test a patient specimen. Accuracy, precision, analytical sensitivity (limit of detection) analytical specificity, analytical measurement range, linearity correlation with a reference laboratory, carry over, recovery, and specimen’s stability are the studies that are performed to validate a laboratory developed test. The validation services cover both moderate (FDA approved) and high complexity (laboratory developed) methods and includes providing a validation plan and acceptance criteria, validation experiment procedure, data analysis of validation results, preparation of final validation reports, assistance for correlation study, and suggestion for sources of reference materials used for the validation studies.
Molecular Diagnostics Tests
Pathogens | NGS | Genotyping |
---|---|---|
Respiratory Pathogen Panel (RPP) | Cardiac panel | Pharmacogenomics panel (PGX) |
Urinary Tract Infection Panel (UTI) | Cancer panel | |
Sexually Transmitted Infections Panel (STI) | Diabetes panel | |
Wound Panel | Neurodegenerative panel (PAD) | |
Toenail Fungal panel | Pharmacogenomics panel (PGX) | |
Womens Health panel | ||
HPV Infections panel | ||
Gastrointestinal panel |
Toxicology Tests
Urine | Saliva | Blood |
(Panels: "Drugs of abuse", "frequently prescribed drugs such as cardiac drugs, cholesterol lowering drugs, anti-hypertensive drugs, pain medication", and "custom panels as required") |